InsiderTrades.com logo
Sarah Boyce net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Sarah Boyce Biography and Net Worth

President & CEO of Avidity Biosciences
Sarah Boyce joined Avidity as President and Chief Executive Officer and a member of the Board of Directors in October 2019. She has more than 25 years of global leadership experience in both pharmaceutical and biopharmaceutical companies. Sarah’s tenure at Avidity has been marked by transformative leadership, starting with the company’s successful Series C funding round and IPO. She continues to drive the company’s evolution from a research and development entity to a biopharmaceutical company through the advancement of three therapies into clinical development and the expansion of the broad utility of the company’s proprietary RNA technology. Prior to joining Avidity, Sarah held the position of president and a member of the board of directors of Akcea Therapeutics. She previously held executive roles in business development and global operations for leading life sciences companies including Ionis Pharmaceuticals, Forest Laboratories, Alexion Pharmaceuticals, Novartis Oncology and Roche. Sarah was named a Healthcare Technology Report Top 25 Biotech CEO in 2022 and has been named one of Fiercest Women in Life Sciences. Sarah currently serves as a member of the board of directors at OmniAb, Inc., Contineum Therapeutics, Inc., and Abcuro, Inc. Sarah holds a BSc (Hons) degree in microbiology from the University of Manchester, England.

What is Sarah Boyce's net worth?

The estimated net worth of Sarah Boyce is at least $9.82 million as of March 20th, 2025. Ms. Boyce owns 305,871 shares of Avidity Biosciences stock worth more than $9,818,459 as of March 26th. This net worth evaluation does not reflect any other assets that Ms. Boyce may own. Additionally, Ms. Boyce receives a salary of $998,880.00 as President & CEO at Avidity Biosciences. Learn More about Sarah Boyce's net worth.

How old is Sarah Boyce?

Ms. Boyce is currently 52 years old. There are 7 older executives and no younger executives at Avidity Biosciences. Learn More on Sarah Boyce's age.

What is Sarah Boyce's salary?

As the President & CEO of Avidity Biosciences, Inc., Ms. Boyce earns $998,880.00 per year. Learn More on Sarah Boyce's salary.

How do I contact Sarah Boyce?

The corporate mailing address for Ms. Boyce and other Avidity Biosciences executives is 10975 N. TORREY PINES RD. SUITE 150, LA JOLLA CA, 92037. Avidity Biosciences can also be reached via phone at 858-401-7900 and via email at amy@juniper-point.com. Learn More on Sarah Boyce's contact information.

Has Sarah Boyce been buying or selling shares of Avidity Biosciences?

During the last quarter, Sarah Boyce has sold $1,276,882.63 in shares of Avidity Biosciences stock. Most recently, Sarah Boyce sold 31,540 shares of the business's stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $31.06, for a transaction totalling $979,632.40. Following the completion of the sale, the chief executive officer now directly owns 305,871 shares of the company's stock, valued at $9,500,353.26. Learn More on Sarah Boyce's trading history.

Who are Avidity Biosciences' active insiders?

Avidity Biosciences' insider roster includes Sarah Boyce (President & CEO), W. Flanagan (Insider), Kathleen Gallagher (Insider), Steven Hughes (Insider), Arthur Levin (Insider), Michael MacLean (Chief Financial and Chief Business Officer), Teresa Mccarthy (Insider), and Tamar Thompson (Director). Learn More on Avidity Biosciences' active insiders.

Are insiders buying or selling shares of Avidity Biosciences?

During the last year, insiders at the biotechnology company sold shares 36 times. They sold a total of 869,535 shares worth more than $31,566,515.23. The most recent insider tranaction occured on March, 20th when insider Steven George Hughes sold 9,578 shares worth more than $297,492.68. Insiders at Avidity Biosciences own 3.7% of the company. Learn More about insider trades at Avidity Biosciences.

Information on this page was last updated on 3/20/2025.

Sarah Boyce Insider Trading History at Avidity Biosciences

See Full Table

Sarah Boyce Buying and Selling Activity at Avidity Biosciences

This chart shows Sarah Boyce's buying and selling at Avidity Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$1.28MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$5M$0$5MTotal Insider BuyingTotal Insider Selling

Avidity Biosciences Company Overview

Avidity Biosciences logo
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $31.96
Low: $31.73
High: $32.75

50 Day Range

MA: $31.31
Low: $27.87
High: $35.11

2 Week Range

Now: $31.96
Low: $21.56
High: $56.00

Volume

445,308 shs

Average Volume

1,334,678 shs

Market Capitalization

$3.84 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.02